# High-Volume Hemodiafiltration (HVHDF): PA/Medical Student Handout

## Learning Objectives

By the end of this module, students will be able to:

1.  Explain the difference between diffusion, convection, and hemodiafiltration
2.  Describe the mechanism of action of HVHDF and why convection volume matters
3.  Interpret clinical evidence from major RCTs (CONTRAST, ESHOL, CONVINCE, Turkish, FRENCHIE)
4.  Calculate convection volume and identify optimization strategies
5.  Compare HVHDF outcomes to conventional hemodialysis
6.  Discuss HVHDF candidacy and implementation considerations

------------------------------------------------------------------------

## Section 1: Historical Context and Evolution

### The Development of HVHDF

- **1967:** Henderson introduced “diafiltration” concept
- **1976:** Fresenius Medical Care begins systematic development
- **1987:** First commercially available online HDF system
- **1998:** Introduction of 4008H system
- **2024:** FDA clearance of 5008X system in United States
- **First U.S. treatment:** January 24, 2025, Wellesley, Massachusetts

**Critical Breakthrough:** Development of cold sterilization technology (DIASAFE®plus ultrafilters) enabling sterile replacement fluid production directly from dialysate, eliminating prohibitive costs of pre-packaged fluids.

------------------------------------------------------------------------

## Section 2: Convection vs. Diffusion - Understanding the Difference

### Diffusion (Traditional Hemodialysis)

**Mechanism:** Solutes move across membrane from high to low concentration

**Advantages:** - Excellent small solute removal (urea, creatinine) - Established technology; widely available - Lower cost than HDF

**Limitations:** - Poor middle-molecule clearance - Cannot remove larger toxic molecules (500-5000 Da) - Beta-2 microglobulin accumulation → dialysis-related amyloidosis

### Convection (HVHDF)

**Mechanism:** “Solvent drag” - solutes move with fluid across membrane

**Key Advantage:** Simultaneous removal of fluid AND solutes of various sizes

**Process:** 1. Large volumes of plasma water removed via ultrafiltration (25+ liters per session) 2. Solutes travel with fluid across membrane (convection) 3. Fluid replaced with sterile substitution fluid 4. Achieves removal across entire molecular weight spectrum

**Clinical Pearl:** Convection is particularly effective for middle-molecular-weight toxins that accumulate in conventional dialysis and contribute to long-term complications.

------------------------------------------------------------------------

## Section 3: Clinical Evidence Base

### The “Dose-Response” Relationship

**Critical Finding:** Mortality benefit is VOLUME-DEPENDENT. Simply doing “HDF” without adequate convection volume provides no benefit.

### Major Randomized Controlled Trials

| Study | Year | N | Mean Conv. Vol. | Primary Outcome | Key Findings |
|----|----|----|----|----|----|
| **CONTRAST** | 2012 | 714 | 19.8 L | All-cause mortality | No overall benefit; post-hoc: \>21.9 L → 38% mortality ↓ |
| **Turkish OL-HDF** | 2013 | 782 | 19.5 L | All-cause mortality + CV | No overall benefit; \>17.4 L → 29% mortality ↓ |
| **ESHOL** | 2013 | 906 | 23.9 L | All-cause mortality | **POSITIVE**: 30% reduction (HR 0.70, p=0.01); dose-dependent |
| **FRENCHIE** | 2016 | 381 | 21.0 L | Intradialytic tolerance | Better tolerance; no mortality difference |
| **CONVINCE** | 2023 | 1360 | 25.5 L | All-cause mortality | **POSITIVE**: 23% reduction (HR 0.77, p\<0.001); cognitive preservation |

### Meta-Analysis Results (Vernooij et al., 2024)

**Individual patient data combining all 5 RCTs:**

| Outcome                               | Convection Volume \>23 L/session |
|---------------------------------------|----------------------------------|
| All-cause mortality reduction         | 37% (p\<0.001)                   |
| Cardiovascular mortality reduction    | 42%                              |
| Infection-related mortality reduction | 49%                              |

### Real-World Evidence

**Fresenius Global Network:** 85,117 patients across 23 countries - 22% all-cause mortality reduction (HDF vs. high-flux HD) - Increases to 30% when high-volume targets achieved

**Brazilian Cohort Study:** 8,391 patients - 27% mortality reduction - Particularly pronounced in patients \<65 years

------------------------------------------------------------------------

## Section 4: Mechanisms of Clinical Benefit

### Enhanced Solute Clearance

**Middle Molecule Removal:** - Beta-2 microglobulin clearance: 73 mL/min (vs. ~30-40 mL/min with HD) - Effective removal of inflammatory mediators (CRP, IL-6, TNF-alpha) - Enhanced clearance across entire molecular weight spectrum

**Clinical Impact:** Reduced dialysis-related complications including amyloidosis and improved immune competence

### Hemodynamic Stability

**Mechanisms:** 1. **Gibbs-Donnan effect:** Sodium retention during ultrafiltration enhances plasma refilling 2. **Cooling effect:** Substitution fluid infusion reduces peripheral vasodilation 3. **Reduced inflammation:** Fewer inflammatory mediators mean less hemodynamic stress 4. **Gradual fluid removal:** Convection distributes fluid removal over longer period

**Outcome:** 50% reduction in symptomatic intradialytic hypotension episodes

### Cardiovascular and Metabolic Benefits

- Improved endothelial function
- Reduced arterial stiffness
- Slower progression of vascular calcification
- Preservation of left ventricular function (less hypertrophy)

### Immune Function Improvement

**Why infection mortality drops 49%:**

1.  Enhanced removal of immunosuppressive middle molecules
2.  Removal of granulocyte inhibitory proteins
3.  Removal of free immunoglobulin light chains
4.  **Result:** Restored immune competence

**Evidence:** HVHDF patients develop higher antibody titers following influenza and SARS-CoV-2 vaccination

------------------------------------------------------------------------

## Section 5: HVHDF Prescription Calculations

### Core Formula and Clinical Application

**Fundamental Relationship:**

$`\text{Convection Volume (L)} = \frac{\left\lbrack \text{Blood Flow (mL/min)} \times \text{Treatment Time (min)} \times \text{Filtration Fraction (\%)} \right\rbrack}{1000} + \text{Net Ultrafiltration (L)}`$

### Worked Example: Standard HVHDF Patient

**Patient:** 75 kg with well-functioning arteriovenous fistula

**Prescribed Parameters:** - Blood flow (Qb): 370 mL/min - Treatment time: 240 minutes (4 hours) - Target filtration fraction: 30% - Net ultrafiltration: 2.5 liters - Dialysate-to-blood flow ratio: 1.2

**Calculations:**

Step 1: Calculate total blood volume processed

    Blood volume = (370 mL/min × 240 min) / 1000
                = 88,800 mL / 1000
                = 88.8 liters

Step 2: Calculate substitution volume (convection component)

    Substitution volume = 88.8 L × 0.30
                        = 26.6 liters

Step 3: Calculate total convective volume

    Convective volume = Substitution volume + Net UF
                      = 26.6 L + 2.5 L
                      = 29.1 liters ✓ (exceeds 23 L target)

Step 4: Determine dialysate flow rate

    Dialysate flow = Blood flow × 1.2
                   = 370 × 1.2
                   = 444 mL/min

Step 5: Verify safe filtration fraction

    Effective FF = Total convection volume / Blood volume
                = 29.1 L / 88.8 L
                = 32.8% ✓ (within safe limits ≤35%)

Step 6: Estimate Kt/V (bonus calculation)

    Diffusive K = ~230 mL/min at Qd:Qb = 1.2
    Convective K = UFR × Sieving coefficient
                 = 110 mL/min × 0.9
                 = 99 mL/min
    Total K = 230 + 99 = 329 mL/min

    For 75 kg patient:
    V = 0.6 × 75 kg × 1000 mL/kg = 45,000 mL

    Kt/V = (329 mL/min × 240 min) / 45,000 mL
         = 1.76 ✓ (exceeds 1.4 target)

### Optimization for Catheter-Limited Patients

**Scenario:** Patient with central venous catheter (limited to 300 mL/min)

**Initial Assessment:**

    Blood volume = (300 × 240) / 1000 = 72.0 liters
    Convection = 72.0 × 0.30 + 2.0 = 23.6 liters (borderline)

**Option A - Increase Filtration Fraction:**

    New FF = 33%
    Convection = (72.0 × 0.33) + 2.0 = 25.8 liters ✓
    Risk: Monitor transmembrane pressure closely

**Option B - Extend Treatment Time (preferred):**

    New time = 270 minutes
    Blood volume = (300 × 270) / 1000 = 81.0 liters
    Convection = (81.0 × 0.30) + 2.0 = 26.3 liters ✓
    Benefit: Maintains safer FF; improves tolerance

### Progressive Implementation Protocol (Incident Patients)

| Parameter        | Week 1  | Week 2 | Week 3 | Week 4 | Week 5 |
|------------------|---------|--------|--------|--------|--------|
| Frequency        | ≥2x     | ≥3x    | ≥3x    | ≥3x    | ≥3x    |
| Time (min)       | 120-180 | ≤180   | ≤240   | ≤240   | ≥240   |
| Blood flow       | ≤150    | ≤200   | ≤250   | ≤300   | ≥340   |
| Dialysate flow   | 300     | 300    | 400    | 400    | ≥500   |
| Substitution (L) | 0       | ≤5     | ≤10    | ≤15    | ≥21    |
| spKt/V target    | None    | None   | None   | ≥1.4   | ≥1.4   |

------------------------------------------------------------------------

## Section 6: Quality Assurance and Troubleshooting

### Monthly Monitoring

**Target:** \>25 L average convection volume; \>80% of sessions \>23 L

**If Convection Volume \<23 L:**

**Scenario:** Qb 320 × 240 × 0.28 / 1000 = 21.5 liters (inadequate)

**Three optimization paths:**

1.  **Increase blood flow** (if access permits)
    - New: 350 × 240 × 0.28 / 1000 = 23.5 liters ✓ (+2.0 L gain)
2.  **Extend treatment time** (preferred if blood flow limited)
    - New: 320 × 270 × 0.28 / 1000 = 24.2 liters ✓ (+2.7 L gain)
3.  **Increase filtration fraction** (risk: TMP monitoring critical)
    - New: 320 × 240 × 0.32 / 1000 = 24.6 liters ✓ (+3.1 L gain)
    - Maximum safe FF: 35% (above this, membrane damage/access stress risk)

------------------------------------------------------------------------

## Section 7: Water Quality and Infrastructure

### Ultrapure Water Standards

**HVHDF requires adherence to ANSI/AAMI/ISO 23500-2019:**

| Parameter                   | Standard                           |
|-----------------------------|------------------------------------|
| **Bacterial count**         | \<0.1 CFU/mL                       |
| **Endotoxin level**         | \<0.03 EU/mL                       |
| **Sterilization assurance** | 6-log reduction (99.9999% removal) |

**Why critical:** High convolution volumes (\>20L) mean high exposure to any water contamination. Even small bacterial/endotoxin loads amplified across massive fluid volumes.

### Online Substitution Fluid Production

**Two-stage ultrafiltration process:** 1. Removes particulates and bacteria 2. Inactivates endotoxins

**Advantage over pre-packaged fluids:** - Eliminates cost barrier (major reason HDF adoption limited in early eras) - Environmental benefit (less packaging/transportation) - Reliable supply chain

------------------------------------------------------------------------

## Section 8: Medication Management in HVHDF

### Antibiotic Dosing Adjustments

**Vancomycin:** Clearance increases with high-volume convection - Standard dosing: 1 gram initially, then 500 mg with each dialysis session (3x/week) - Monitor therapeutic drug levels

**Piperacillin/Tazobactam and Ceftazidime:** - Dose as if GFR = 10-20 mL/min - Post-dialysis dosing strategy preferred

**Clinical Pearl:** Enhanced middle-molecule clearance with HVHDF means dosing adjustments necessary to prevent sub-therapeutic levels. Pharmacist consultation recommended.

### Other Medications

- **Small-molecule drugs:** Minimal change in clearance
- **Protein-bound drugs:** Unaffected regardless of modality
- **Moderate molecular weight, low protein binding:** May experience enhanced removal; monitor therapeutic levels

------------------------------------------------------------------------

## Section 9: Patient Selection and Implementation

### Optimal Candidates for HVHDF

**Strongest indications:** - Well-functioning AVF (supports 350-400+ mL/min) - Active transplant candidates (requires cardiovascular protection) - History of recurrent infections - Hemodynamic instability or heart failure - Evidence of dialysis-related amyloidosis - Significant elevation of middle-molecule markers

**Broader application:** Evidence supports implementation across diverse populations, though quality data from elderly and highly comorbid patients still being collected through H4RT registry.

### Implementation Strategy

**Phased approach recommended:**

1.  **Phase 1:** Target patients most likely to achieve therapeutic volumes (AVF patients)
2.  **Phase 2:** Expand to graft patients as staff expertise develops
3.  **Phase 3:** Extend to catheter-dependent patients with extended treatment times
4.  **Ongoing:** Monitor quality metrics; provide continuous staff education

------------------------------------------------------------------------

## Section 10: Cost-Effectiveness and Environmental Impact

### Economic Sustainability

**CONVINCE Trial Economic Analysis:** - Incremental cost-effectiveness: €27,068-36,751 per QALY - Below €50,000 threshold considered cost-effective in Europe - Offset by: Reduced hospitalizations, fewer medications, improved longevity

### Environmental Considerations

**Optimized Dialysate Prescription Impact:**

Traditional HD:

    Qd:Qb = 1.5
    Qb 370 mL/min → Qd 555 mL/min
    Session consumption: ~133 liters

Optimized HVHDF:

    Qd:Qb = 1.2
    Qb 370 mL/min → Qd 444 mL/min
    Session consumption: ~107 liters
    Savings: 26 liters per session (19.5% reduction)

**Additional benefits:** Reduced water usage, less waste generation, lower carbon footprint from transport

------------------------------------------------------------------------

## Practice Questions

**1.** A 70-kg patient on HVHDF has these parameters: - Blood flow: 350 mL/min - Treatment time: 240 minutes - Filtration fraction: 32% - Net ultrafiltration: 2.0 L

Calculate convection volume: - A) 18.2 L - B) 23.5 L - C) 28.8 L - D) 33.2 L

**Correct Answer: B) 23.5 L** *Calculation: \[(350 × 240 × 0.32) / 1000\] + 2.0 = 26.88 + 2.0 = 28.88 ≈ 29 L… Wait, let me recalculate. (350 × 240 × 0.32) / 1000 = 26.88 L; + 2.0 = 28.88 L. Actually C is correct.*

**Correct Answer: C) 28.8 L**

------------------------------------------------------------------------

**2.** Which of the following RCT findings demonstrated a statistically significant mortality benefit with HVHDF? - A) CONTRAST study - B) Turkish OL-HDF study - C) ESHOL study - D) FRENCHIE study

**Correct Answer: C) ESHOL study** *ESHOL explicitly targeted high-efficiency HDF with mean convection volumes of 23.9 L/session and demonstrated a 30% reduction in all-cause mortality (p=0.01).*

------------------------------------------------------------------------

**3.** What is the critical convection volume threshold for demonstrating mortality benefit based on meta-analyses of RCTs? - A) \>15 L/session - B) \>20 L/session - C) \>23 L/session - D) \>30 L/session

**Correct Answer: C) \>23 L/session** *The meta-analysis by Vernooij et al. (combining all 5 RCTs) found greatest benefit at \>23 L/session with 37% all-cause mortality reduction.*

------------------------------------------------------------------------

**4.** A dialysis facility implements HVHDF but finds only 40% of sessions achieving \>23 L convection volume. What is the most likely issue? - A) Water purity standards not met - B) Patient selection of those without adequate access - C) Insufficient treatment time or blood flow - D) Dialysate flow rate too low

**Correct Answer: B) Patient selection of those without adequate access** *HVHDF requires robust vascular access. If most patients have AVGs or catheters (limiting blood flow), convection targets become difficult. Retrospective assessment of access types would help; if many catheters or grafts, extend treatment times for those; prioritize new AVF placements.*

------------------------------------------------------------------------

## Key Takeaways

1.  **Volume matters:** HVHDF benefit is dose-dependent; \<23 L/session provides no advantage over conventional HD

2.  **Superior outcomes:** 37% all-cause mortality reduction, 49% infection-related mortality reduction when \>23 L achieved

3.  **Convection principle:** Simultaneous removal of excess fluid AND large molecular toxins; prevents middle-molecule accumulation

4.  **Implementation critical:** Quality assurance tracking convection volumes, not just Kt/V; staff training essential

5.  **Infrastructure investment:** Ultrapure water systems required; upfront capital expenditure justified by long-term outcomes

6.  **Cardiovascular benefit:** 50% reduction in intradialytic hypotension; improved cardiac function preservation

------------------------------------------------------------------------

## Related Resources

- HVHDF Comprehensive Analysis
- Kidney Replacement Therapy Report
- Nephrology Hub

------------------------------------------------------------------------

*Created for PA and medical students as part of advanced dialysis education. For implementation decisions, consult current guidelines, institutional resources, and attending nephrologists.*

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [High-Volume Hemodiafiltration](https://urinenephrology.org/mastery/dialysis-advanced/hvhdf.html)


---

[Website version](https://urinenephrology.org/student-resources/dialysis/hvhdf-student-handout.html) · Markdown synchronized October 3, 2026.